|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date18 Aug 2017 |
A Phase 1, Randomized, Open-Label, Replicate, Crossover Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
100 Clinical Results associated with URAT1 x XO x SLC22A11
100 Translational Medicine associated with URAT1 x XO x SLC22A11
0 Patents (Medical) associated with URAT1 x XO x SLC22A11